

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Series of 49 French Pediatric Cases

Eve Bedouelle, Benoit Ben Said, Florence Tetart, Brigitte Milpied, Anne Welfringer-Morin, Annabel Maruani, Benoit Catteau, Frédéric Dezoteux, Delphine Staumont-Sallé, Juliette Mazereeuw-Hautier, et al.

▶ To cite this version:

Eve Bedouelle, Benoit Ben Said, Florence Tetart, Brigitte Milpied, Anne Welfringer-Morin, et al.. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Series of 49 French Pediatric Cases. Journal of Allergy and Clinical Immunology: In Practice, 2022, 10.1016/j.jaip.2021.07.025. hal-03342672

HAL Id: hal-03342672 https://hal.science/hal-03342672v1

Submitted on 8 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Version of Record: https://www.sciencedirect.com/science/article/pii/S221321982100828X Manuscript_5b0ea862f811028b1b9f3e5f3a0c9303

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) :

2

Series of 49 French pediatric cases

3

5	
4	Eve Bedouelle ¹ , Benoit Ben Said MD ² , Florence Tetart MD ^{3,4} , Brigitte Milpied MD ⁵ , Anne Welfringer-
5	Morin MD ⁶ , Annabel Maruani MD, PhD ⁷ , Benoit Catteau MD ⁸ , Frédéric Dezoteux MD ⁸ , Delphine
6	Staumont-Sallé MD, PhD ⁸ , Juliette Mazereeuw-Hautier MD, PhD ⁹ , Claire Abasq MD ¹⁰ , Christine
7	Chiaverini MD ¹¹ , Juliette Delaunay MD ¹² , Stéphanie Mallet MD ¹³ , Benoit Sterling MD ¹⁴ , Eve Puzenat
8	MD ¹⁵ , Margot Raynal MD ³ , Evelyne Collet MD ¹⁶ , Claire Bernier MD ¹ , on behalf of the Groupe FISARD
9	de la Société Française de Dermatologie and of the Groupe de Recherche de la Société Française de
10	Dermatologie Pédiatrique
11	
12	1 Service de Dermatologie, Hôtel Dieu, Centre Hospitalier Universitaire de Nantes, Nantes, France
13	2 Service de Dermatologie, Centre Hospitalier Universitaire de Lyon, Lyon, France
14	3 Service de Dermatologie, Centre Hospitalier Universitaire de Rouen, Rouen, France
15	4 Centre Erik Satie, unité d'allergologie, Centre Hospitalier Universitaire de Rouen, Rouen, France
16	5 Service de Dermatologie et Dermatologie Pédiatrique, Hôpital Saint-André et Pellegrin, Bordeaux,
17	France
18	6 Service de Dermatologie, centre de référence des génodermatoses et des maladies rares à
19	expression cutanée (MAGEC), Assistance publique hôpitaux de Paris, Hôpital Necker-Enfants malades
20	Université de Paris, Paris, France
21	7 Université de Tours, INSERM 1246-SHPERE, Service de Dermatologie, Unité de Dermatologie
22	Pédiatrique, Centre Hospitalier Universitaire de Tours, 37000 Tours, France

- 23 8 Service de Dermatologie CHU Lille, Univ. Lille, INFINITE U1286 Inserm F-59000 Lille
- 24 9 Service de Dermatologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
- 25 10 Service de Dermatologie, Centre Hospitalier Régional Universitaire de Brest, Brest, France

- 26 11 Service de Dermatologie, Centre Hospitalier Universitaire de Nice, Nice, France
- 27 12 Service de Dermatologie, CHU d'Angers site Larrey, Angers, France
- 28 13 Service de Dermatologie et cancérologie cutanée, Hôpital de la Timone, AP-HM, Aix-Marseille
- 29 Université, Marseille, France
- 30 14 Services de pédiatrie et pneumologie pédiatrique, hôpital de La Timone-Enfants et hôpital Nord,
- 31 AP-HM, Aix-Marseille Université, Marseille, France
- 32 15 Service de Dermatologie, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France
- 33 16 Service de Dermatologie, Hôpital Le Bocagen, Centre Hospitalier Régional Universitaire de Dijon,
- 34 Dijon, France
- 35
- 36 **Corresponding authors**: Eve Bedouelle & Dr Claire Bernier. Service de Dermatologie, 1 place Alexis
- 37 Ricordeau, CHU de Nantes, Nantes.
- 38 Telephone: +33 (0)6 31 59 87 71 Fax: +33 (0)2 40 08 48 06 Email: eve.bedouelle@gmail.com;
- 39 claire.bernier@chu-nantes.fr
- 40 This article has no funding source.
- 41 The authors have no conflict of interest to declare.
- 42 Word Count Abstract: 231 Text: 3106

43 Abstract

Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare and
potentially fatal adverse drug reaction. It can be difficult to diagnose, even more so among
children, since symptoms may mimic other commonly encountered pediatric conditions.

47 **Objective**: To describe clinical and laboratory features of DRESS syndrome in the pediatric

48 population (\leq 18 years of age), establish causative agents and treatment modalities.

49 **Methods**: Multicenter retrospective study of probable and definite DRESS cases (RegiSCAR ≥

4) in children hospitalized in 15 French University Hospitals between 2000 and 2020.

Results: We included 49 cases. All children had fever and rash, 69.4% had lymphadenopathy and 65.3% had facial edema. The most common organ affected was the liver (83.7%). Treatment consisted in topical corticosteroid only for 30.6%, systemic corticosteroid for 55.1%; 12.2 % received IVIg. Among culprit drugs of probable and certain probability, 65% were antibiotics and 27.5% antiepileptics, with a median time to DRESS symptom onset after initiation of 15 days (13 days with antibiotics and 21 days with antiepileptics). Twenty-seven children had allergy assessment for causative agents: 65.4% had positive tests.

58 **Conclusions**: The culprit drugs are frequently antibiotics and antiepileptic drugs and onset is 59 often less than two weeks after the treatment starts, especially with antibiotics. Treatment 60 with topical corticosteroids appears sufficient in the least severe cases. Treatment by 61 systemic corticosteroid therapy remains the reference treatment in case of severe organ 62 damage.

63 Highlights box

64 1. What is already known : Drug reaction with eosinophilia and systemic symptoms (DRESS) 65 is a rare and potentially fatal adverse drug reaction. It can be difficult to diagnose, even 66 more so among children, since symptoms may mimic other commonly encountered pediatric 67 conditions. 68 2. What does this article add to our knowledge : This case series shows that clinical and 69 biological characteristics of DRESS syndrome in the pediatric population are similar to those 70 of adults. The onset of firsts symptoms can be less than two weeks after the treatment 71 starts, especially with antibiotics.

72 3. How does this study impact current management guidelines : Treatment with topical

corticosteroids appears sufficient in the least severe cases. Patch tests allow to confirm the

imputability of the molecule in the majority of tested cases.

75

76 Key words

- 77 Drug Reaction with Eosinophilia and Systemic Symptoms; DRESS; pediatric, children; antibiotics,
- 78 antiepileptic drugs

79 Abbreviations

- 80 APS: Naranjo Adverse Reaction Probability Scale
- 81 CMV: Cytomegalovirus
- 82 DRESS: Drug Reaction with Eosinophilia and Systemic Symptoms
- 83 EBV: Epstein Barr Virus
- 84 FISARD: French Investigators for Skin Adverse Reactions to Drugs group
- 85 GNEDS: Groupe Nantais d'Ethique dans le Domaine de la Santé (Nantes Health Ethics Group)
- 86 GRC-SFDP: Groupe de Recherche Clinique de la Société Française de Dermatologie
- 87 Pédiatrique (Clinical Research Unit of the French Society of Pediatric Dermatology)
- 88 HH : Human Herpes Virus
- 89 HLH : Haemophagocytic lymphohistiocytosis
- 90 IDR: Intra Dermo Reaction
- 91 IVIg: Intravenous Immunoglobulin
- 92 PCR: Polymerase Chain Reaction
- 93 PTs: Patch Tests
- 94 SC: Systemic Corticosteroid
- 95 TS: Topical corticosteroids

96 Introduction

97 Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare and potentially 98 fatal adverse drug reaction classified among severe cutaneous adverse reactions (SCARs) (1). 99 It is classified under delayed drug-induced hypersensitivity reaction characterized by fever, 100 rash, lymphocyte activation (lymph node enlargement, 'atypical' activated lymphocytes), 101 eosinophilia and various visceral dysfunctions with a risk of multi-organ failure. The 102 physiopathological mechanisms of DRESS syndrome result from the interaction between one 103 (or more) drug(s) or their metabolites and an immune receptor (Human Leukocyte Antigen 104 or T cell receptors) leading to a T cell-mediated response (2-4). Reactivations of herpes virus, 105 especially HHV-6, are frequently observed but it remains unclear whether the viral 106 reactivation (or a primary viral infection) is the trigger event of the DRESS syndrome or 107 whether viral reactivation is a consequence of the DRESS (5–8). Diagnosis can be delayed 108 because of the variable clinical presentation, and the similarities with infection or 109 lymphoproliferative diseases. Its incidence among the pediatric population is unknown and 110 its knowledge has for a long time been based on case reports and small cases series. In 2019, 111 Metterle et al. (9) published a review of the literature collating 130 pediatric cases. The most 112 common clinical presentations included fever, a morbilliform rash and lymphadenopathy. 113 The liver was the most frequently involved organ (80%). Time from treatment initiation to 114 first symptoms was three to 60 days (average 24 days), and DRESS syndrome was secondary 115 to antiepileptics in 50% and antibiotics in 30.8% of cases. Our study aims to analyze the 116 epidemiology, clinical and laboratory features, identify drugs associated with the reaction 117 and the therapeutic management of DRESS syndrome among children.

118 Materials and methods

119 We performed a retrospective study of DRESS syndrome diagnosed between 2000 and 2020 120 among pediatric population in 15 French hospitals. The clinical study was conducted in 121 accordance with the relevant versions of the French Public Health Code, national and 122 international good clinical practice (GCP) guidelines, and the Declaration of Helsinki, each in 123 the applicable version. Our study was submitted to and approved by the local Research 124 Ethics Committee (GNEDS) of Loire-Atlantique on Septembre 1, 2020. The Regiscar score 125 (10) was used to establish the diagnosis of DRESS (Table E1, available in Online Repository 126 Text). The inclusion criteria were: (i) diagnosis of DRESS, (ii) RegiSCAR score ≥ 4 , (iii) age ≤ 18 127 years and (iv) at least one suspected drug. Standardized questionnaires (available in Online 128 Repository Text) were used to collect data from the patient's medical record. Investigators 129 were members of Clinical Research Unit of the French Society of Pediatric Dermatology 130 (GRC-SFDP)) or the French Investigators for Skin Adverse Reactions to Drugs group (FISARD) 131 of the French Society of Dermatology. In each centre, cases were identified by 132 dermatologists, allergologists, pediatricians and the pharmacovigilance centre. We collected 133 data about demographics, suspected culprit drugs, clinical and laboratory data, treatment of 134 DRESS and testing suspect drugs. Liver involvement was defined by a twofold or greater 135 increase of transaminases compared to normal values. Kidney involvement was defined by 136 elevated creatinine, proteinuria, anuria or electrolyte disturbance. The different drugs, dates of introduction and discontinuation were documented. Suspected drugs were defined as all 137 138 drugs started within 12 weeks before the onset of the rash and still administered or stopped 139 less than five half-lives before rash onset. We determined the causality of drugs according to 140 the Naranjo Adverse Reaction Probability Scale (APS) (11). In the case of a confirmed 141 reaction to a drug, other drugs with compatible timelines were not excluded from the list of suspect drugs. All the data were collected using Microsoft Excel. Analyses was performed

- 143 using SAS statistical software (SAS Institute Inc., Cary, North Carolina, USA). Quantitative
- 144 data are expressed as median ± range and qualitative data in percentage (%).

145 **Results**

We identified 64 potential DRESS cases from the medical records of 15 French hospitals. Of these, a total of 15 cases were excluded : one case was a DRESS-like rash (12,13) during viral infection and lacked a causative agent, 11 cases had a RegiSCAR scores <4 and three cases had insufficient data. Finally 49 cases were included in the study.

150

151 Characteristics

152 Patient's and DRESS syndrome's characteristics are summarized in Table 1. The median age 153 was eight years (range: 5 weeks - 18 years) and 44.9% were male. Three children (6.1%) had 154 previously experienced a drug-induced skin reaction (two with unspecified rash, on with 155 urticaria), two of them to the same drug as the DRESS syndrome (one with 156 sulfamethoxazole-trimethoprim and one with penicillin). Eight children (16.3%) were 157 immunocompromised. The DRESS occurred during a hospital stay in 24.5%. According to the 158 RegiSCAR score, 55.1% were definite and 44.9% were probable DRESS syndrome 159 (characteristics of each group are available in Table E2 in Online Repository Text). The 160 diagnosis of DRESS syndrome was made in a median time of six days after rash onset (range: 161 0-28). A differential diagnosis was presumed for 22 children (44.9%) (viral infection in 162 63.6%, Kawasaki disease in 22.7%). The majority of diagnoses were made by dermatologists 163 (57.1% of cases), while pediatricians provided the diagnosis in 12.1% of cases (Table 1).

164

As described in Table 2, fever and rash were documented in all children. In 95.4% of cases, the rash covered more than 50% of the body surface area. A morbilliform exanthema was described in 67.3% (monomorphic in 66.7% (Figure 1), polymorphic in 33.3%, including purpura, target-like lesions, eczema-like lesions, blisters and pustules). Erythroderma was 169 described in 14.3%. Pruritus was reported in 67.3% and facial edema in 65.3% (Figure 1). Lymphadenopathy was observed in 69.4%. Mucosal involvement was described in 40.8% 170 171 (associated cheilitis in 30.6% (Figure 2), mouth ± throat involvement in 16.3% and 172 conjunctivitis in 10.2%). The most commonly affected organs were the liver (41 children, 173 83.7%), kidneys (13 children, 26.5%; associated with isolated proteinuria in 54% of cases and 174 moderate creatinine elevation in 38% of cases), lungs (11 children, 22.4%) and gastrointestinal tract (five children, 10.2%). Myocarditis was described in one case and 175 176 meningitis in one. Biological abnormalities are detailed in Table 3. Eosinophilia (absolute 177 count > 500/mm³) was present in 85.7% and atypical lymphocytes were observed in 49%. An 178 investigation for viral reactivation or primary infection was conducted for 42 children (18 by 179 serology and polymerase chain reaction [PCR], 16 PCR only and eight serology only). Among 180 the 34 children who were investigated by PCR, 17 (50%) were positive. Among them, 32 181 were tested for HHV-6 : seven were positive (21.9%); four were positive for Parvovirus B19, 182 four for Epstein-Barr virus (EBV), two for HHV-7 and two for cytomegalovirus (CMV), 183 including two children with co-infection EBV and CMV. Twelve children (24.5%) had 184 biological criteria for haemophagocytic lymphohistiocytosis (HLH) (14).

A skin biopsy was performed in 29 cases (59.2%). The analysis of histopathology was available for 27 biopsies (Table E3, available in Online Repository Text): the most common pattern included an epidermis with cytoid bodies and lymphocytic exocytosis, sometimes spongiosis. The dermis was classically the place of a perivascular lympho-histiocytic inflammatory infiltrate. The presence of eosinophils was not a consistent finding (33.3% of biopsies).

191

192 **Course and treatment**

193 Median duration of eruption was 20.5 days (range: 4-90), this persisted more than 15 days in 194 72.5%. Median time from the beginning of the rash to maximal count of eosinophils was 10 195 days (range: 0-35), and to maximal rate of transaminase elevation 11 days (1-35). Median 196 time of resolution of transaminase was 28 days (7-68) after onset of rash (Figure 2). 197 Seventeen (34.7%) children were transferred to an intensive care unit (median duration stay 198 five days, range: 1-26). One child died from cardiopulmonary arrest due to myocarditis and 199 one child died from septic and hypovolemic shock complicated by multivisceral failure 200 syndrome in a context of erythroderma. Median duration of hospitalization was 13 days 201 (range: 3-60): 10 days (range: 3-39) for community cases and 22 days (range: 12-60) for 202 hospital cases. Specific treatments of DRESS syndrome are summarized in Table 1; 51% 203 received topical corticosteroid (TS) and 55.1% systemic corticosteroids (SC) (median duration 204 for SC: 42.5 days (range: 1-546), introduced at a dose of 2mg/kg in 36.4% of cases, 1mg/kg in 205 54.5% and 0.5 mg/kg in 9.1% of cases). Children treated with TS only appeared to have less 206 severe presentation than those who received SC therapy with a shorter duration of rash (16 207 days versus 23.5 days, respectively) and 13% of hospitalization in intensive care versus 48%, 208 respectively. Six cases (12.2%) received intravenous immunoglobulin (IVIg) (for three 209 patients, this was due to the initial hypothesis of Kawasaki disease) and two cases (4.1%) 210 received ciclosporin. Thirty-six patients (73.5%) were followed after discharge : the median 211 number of consultations was three (range: 1-10) and the median follow-up was 8.8 months (range: 3 days - 5.8 years). A relapse was noted in 11 cases (22.4%), within a delay of six 212 213 weeks to six months after the resolution of eruption for six cases (54.5%). Relapse was 214 attributed to the decrease or cessation of corticosteroid therapy in three cases (27.3%). 215 Long-term sequelae were observed in five patients (10.2%): one with vitiligo, one with 216 hyperpigmentation and one systemic lupus revealed a year after resolution of DRESS (with 217 anti-SSA and anti-SSB antibodies). Two children presented complications of steroids : the 218 first child presented with corticoid-induced hypertension; he received 46 days of 219 corticosteroids for the management of a severe DRESS syndrome with liver involvement 220 (resolution 36 days after the onset of the rash), HLH and bronchial syndrome. He was 221 receiving long-term treatment with inhaled fluticasone. The second child presented with 222 corticotropic insufficiency and diabetes mellitus; he received one year and six months of corticosteroids for a chronic DRESS (multiple episodes of recurrence on attempts to decrease 223 224 the corticosteroids) with lung (alveolar infiltrate) and liver involvement.

225

226 Causative drugs

Among the 85 medications suspected of inducing DRESS, 49 (57.6%) were antibiotics and 17 (20%) antiepileptics. The median time of DRESS onset after introduction was 13 days (range: 0-70) (antibiotics: 12, range: 0-44; antiepileptics: 21, range : 4-52). If one calculates this for drugs of definite or probable imputability only according to the APS (11) (40 drugs): 26 (65%) were antibiotics and 11 (27.5%) antiepileptics. The delay of onset was 15 days (range: 1-44) (antibiotics: 13, antiepileptics: 21) and 47.5% of the drugs have a delay < 15 days (13 antibiotics and five antiepileptics).

Suspect drugs were continued after the onset of rash for a median duration of four days (range: 0-88), although when considering the drug classes separately, this is three days for antibiotics rising to 10 days for antiepileptics. A table summarizing all the culprit drugs (Table E4) is available in Online Repository Text.

238

239 **Tests**

240 Allergy assessment was performed for 26 children (53%) in a median time of seven months 241 (range: 2-39 months) after hospital discharge and was conducted according to The European 242 Network on Drug Allergy (ENDA) and European Academy of Allergy and Clinical Immunology 243 (EAACI) guidelines (15,16). 23 had patch tests (PTs), nine had intradermal test (IDR), three 244 had prick test, two had lymphocyte transformation test (LTT) and two had oral provocation. 245 Tests were positive for 17 children (65.4%): PTs were positive for 15 children (61.5%), among 246 them a child had a LTT positive for another drug (co-sensitization for vancomycin and 247 sulfamethoxazole-trimetoprim) and both children subjected to oral provocations were 248 positive (one of these provocation tests resulted in a recurrence of the DRESS syndrome). 249 Two children had positive immediate but not delayed IDR (oxacillin and capsofugin, the 250 latter also positive for prick test) while the patch tests were negative. These two children 251 were not included in the positive tests due to the absence of a delayed reaction.

252

253 **Discussion**

254 Although the frequency cannot be specified through this descriptive cohort, we have 255 identified 49 cases of probable or definite DRESS syndromes among pediatric population 256 over the last twenty years in France. This diagnosis, which was rarely mentioned in children, 257 seems to be better known (75% of the cases in our cohort have been described in the last 258 five years). This cohort provides a detailed description of the clinical and biological 259 presentation, the course and the causative agents of pediatric DRESS and allows us to 260 illustrate the similarities and differences between children and adults (Table E5, available in 261 Online Repository Text).

The most frequent clinical manifestations in our study were fever, rash, lymphadenopathy and facial edema and the most common affected organ was the liver (83.7%) – confirming 264 observations made in previous adults (17,18) and pediatric (9,19–23) series. The percentage 265 of lung involvement (22.4%) is comparable to the adult cohorts described by Lee et al. (24) 266 and Kardaun et al. (18) (20% and 32% respectively); the most common manifestations were 267 interstitial infiltrates (27%) and acute respiratory distress syndrome (27%) as described in 268 the systematic review by Taweesedt and al. (25). Five children presented with diarrhea 269 (10%), one of them with vomiting. None of them had histological investigations. Digestive 270 tract involvement is poorly described in the different cohorts of adults or children. When 271 described, the symptoms are non-specific and are not investigated. In the study by Newell et 272 al (19), 44% of children presented with digestive involvement, including 57% with vomiting, 273 29% with diarrhea and 29% with bloody diarrhea. A few cases of oesophagitis and/or 274 inflammatory colitis up to and including ulcerative colitis have been reported (26,27). The 275 number of HHV-6 reactivations (22%) was lower than in previous studies (43% and 36%) 276 (9,18).

The diagnosis of DRESS was essentially made by dermatologist and median diagnostic delay after onset of rash was six days resulting in a frequent delay in the discontinuation of the culprit drug(s). We highlight that the biological picture worsens after apparition of skin symptoms, in spite of stopping the culprit drug (Figure 2).

281

287

We report a high prevalence of antibiotic-related cases with the penicillin class, sulfamethoxazole-trimethoprim and vancomycin at the top of the list. Among antiepileptics, carbamazepine was the main drug responsible, as found in previous studies (9,17–19). It has long been accepted that DRESS occurs within two to eight weeks after the introduction of medication (27,28). In our study the latency period is shorter and 47.5% of the drugs of

definite or probable imputability have a latency period < 15 days. Our study suggests that

14

DRESS syndrome among pediatric population can occur less than 15 days after drug
introduction. These results are consistent with those reported in other series (9,16,19,22)
and the study by Soria et al.(30).

291

292 There is currently no consensus on the therapeutic management of DRESS, as there are no 293 randomized controlled trials evaluating the efficacy of the different treatments. Topical 294 corticosteroids (TS) are proposed for non-severe DRESS, whilst in the case of internal organ 295 involvement, treatment with a systemic corticosteroid (SC) is recommended (31,32). In our 296 study, 31% received only TS. These cases appeared to be less severe than those who 297 received SC therapy (13% of hospitalization in intensive care versus 48%). Furthermore, the 298 rash appears to resolve more rapidly (16 days versus 23.5 days). These results are consistent 299 with those of Funck-Brentano et al.(33) and Uhara et al.(34) who suggested that TS can be 300 used in patients with non-severe DRESS. Treatment with SC might favor relapse (30) and is 301 often prolonged and carries an infection risk (35,36). In the various observational studies and 302 literature reviews, SC have been used in 43-100% of cases in both adults and children 303 (9,17,19, 21, 23), while the use of TS is rarely mentioned (9% of children in the cohort by 304 Newell et al. (19) and 21% in the cohort by Bessmertny et al. (21)).

In our study, six children received IVIg, with a median duration of the rash of 15 days (versus 21 days for the other cases in the cohort). Treatment with IVIg has been described in a few severe cases with variable results (37–39). A recent series of seven pediatric cases showed that a treatment combining IVIg and SC led to a rapid improvement of the children's general condition (40). On another hand, in a series of six adult cases treated with IVIg alone, five patients had severe adverse events, suggesting that IVIg must not be used as stand-alone treatment in DRESS (37). Ciclosporin has been proposed when SC are contraindicated or in 312 cases of corticosteroid resistance. It has been reported in a few cases as a successful 313 alternative (41–43). Ciclosporin was received by two children in our case series. In the first 314 case, this was because of a non-response to SC and IVIg treatment, with resolution of the 315 rash one month after starting ciclosporin. For second child, ciclosporin was started after 9 316 months of chronic evolution of the DRESS syndrome, but the introduction of ciclosporin 317 combined with continued corticosteroid therapy did not control the disease, and the child 318 died from septic and hypovolemic shock complicated by multivisceral failure syndrome in a 319 context of erythroderma 18 months after onset of DRESS.

320

In a study that retrospectively examined 43 cases of DRESS syndrome, Chen et al. (44) reported 11.5% of long-term sequelae and found that autoimmune sequelae were more common in younger patients. In our study, five patients developed long-term sequelae, including two related to the prolonged use of corticosteroids and two autoimmune complications: one vitiligo and one systemic lupus, which has already been reported in the literature (44–47).

327

Allergy assessment, which consisted of patch tests for the majority of children, were positive in 65.4% of cases, data comparable to the literature (48, 49). No delayed IDR was positive in our cohort.

331

The most important limitation of this study is the retrospective analysis of medical records in which data may be missing. In addition, since the recruitment of the included cases was based on volunteered by members of the SFDP and the FISARD group, this approach will have missed cases (recruitment bias). Finally, investigators were mainly dermatologists and it is possible that some rare cases of DRESS with visceral manifestations but minimal orabsent cutaneous symptoms were not recruited.

338

339 **Conclusion**:

340 Due to the diversity of its clinical and biological presentation, the diagnosis of DRESS 341 syndrome is difficult. This often leads to a delay in diagnosis and cessation of culprit drugs.

342 This series shows that the onset of DRESS syndrome in the pediatric population is often less 343 than two weeks after the treatment starts, especially when it involves antibiotics. The initial 344 management will consist of stopping suspected culprit drug(s), i.e. those introduced in the 345 last three months. Clinical and biological signs of DRESS should be closely monitored over a 346 long period of time, as the condition may worsen despite the cessation of the drug(s). 347 Treatment with topical corticosteroids appears sufficient in the least severe cases. 348 Treatment by systemic corticosteroid therapy remains the reference treatment in case of 349 severe organ damage, and the place of IVIg remains to be determined.

350 Acknowledgments

- 351 We are indebted to all patients and their parents and to the collaborating physicians for
- 352 their important contribution to this work.

353 References

354 1. Cho Y-T, Yang C-W, Chu C-Y. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): 355 An Interplay among Drugs, Viruses, and Immune System. Int J Mol Sci. 2017 Jun 9;18(6):1243. 356 White KD, Chung W-H, Hung S-I, Mallal S, Phillips EJ. Evolving models of the 2. 357 immunopathogenesis of T-cell mediated drug allergy: the role of host, pathogens, and drug 358 response. J Allergy Clin Immunol. 2015 Aug;136(2):219-34. 359 3. Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. Drug Hypersensitivity 360 and Human Leukocyte Antigens of the Major Histocompatibility Complex. Annu Rev Pharmacol 361 Toxicol. 2012 Feb 10;52(1):401–31. 362 4. Redwood AJ, Pavlos RK, White KD, Phillips EJ. HLAs: Key regulators of T-cell-mediated drug 363 hypersensitivity. HLA. 2018;91(1):3–16. 364 Picard D, Janela B, Descamps V, D'Incan M, Courville P, Jacquot S, et al. Drug reaction with 5. 365 eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl 366 Med. 2010 Aug 25;2(46):46ra62. 367 6. Criado PR, Criado RFJ, Avancini J de M, Santi CG. Drug reaction with Eosinophilia and Systemic 368 Symptoms (DRESS) / Drug-induced Hypersensitivity Syndrome (DIHS): a review of current 369 concepts. An Bras Dermatol. 2012 Jun;87(3):435–49. 370 7. Shiohara T, Ushigome Y, Kano Y, Takahashi R. Crucial Role of Viral Reactivation in the 371 Development of Severe Drug Eruptions: a Comprehensive Review. Clin Rev Allergy Immunol. 372 2015 Oct;49(2):192-202. 373 8. Descamps V, Ranger-Rogez S, Musette P, Barbaud A. Le DRESS (drug reaction with eosinophilia 374 and systemic symptoms): une synergie médicaments-virus qui peut conduire en réanimation. 375 Réanimation. 2011 May;20(3):223-7. 376 Metterle L, Hatch L, Seminario-Vidal L. Pediatric drug reaction with eosinophilia and systemic 9. 377 symptoms: A systematic review of the literature. Pediatr Dermatol. 2020 Jan;37(1):124-129. 378 Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. 10. 379 Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: 380 does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609-611.

- 11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt
 DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther.
 1981 Aug;30(2):239-45.
- Descamps V, Brunet-Possenti F. Drug Reaction with Eosinophilia and Systemic Symptoms or
 Virus Reactivation with Eosinophilia and Systemic Symptoms. Pediatr Dermatol. 2016
 Sep;33(5):562.
- 387 13. Dondi A, Parladori R, Mori F, Liccioli G, Bassi A, Lanari M et al. Viral rashes mimicking drug
 388 reaction with eosinophilia and systemic symptoms syndrome in children after β-lactams intake:
 389 a diagnostic challenge. Eur J Pediatr. 2021 Mar 9.
- Risma KA, Marsh RA. Hemophagocytic Lymphohistiocytosis: Clinical Presentations and
 Diagnosis. J Allergy Clin Immunol Pract. 2019 Mar;7(3):824-832.
- Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin
 test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002 Jan;57(1):45-51.
- 16. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB et al.;
- 395 ENDA/EAACI Drug Allergy Interest Group. Skin test concentrations for systemically
- administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013
 Jun;68(6):702-12.
- Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS Syndrome: A
 Literature Review. Am J Med. 2011 Jul;124(7):588–97.
- Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with
 eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction.
 Results from the prospective RegiSCAR study. Br J Dermatol. 2013 Nov;169(5):1071–80.
- 403 19. Newell BD, Moinfar M, Mancini AJ, Nopper AJ. Retrospective Analysis of 32 Pediatric Patients
 404 with Anticonvulsant Hypersensitivity Syndrome (ACHSS). Pediatr Dermatol. 2009;26(5):536–46.
- 405 20. Ahluwalia J, Abuabara K, Perman MJ, Yan AC. Human herpesvirus 6 involvement in paediatric
 406 drug hypersensitivity syndrome. Br J Dermatol. 2015;172(4):1090–5.
- 407 21. Bessmertny O, Hatton RC, Gonzalez-Peralta RP. Antiepileptic hypersensitivity syndrome in
 408 children. Ann Pharmacother. 2001 May;35(5):533-8.

- Sasidharanpillai S, Sabitha S, Riyaz N, Binitha MP, Muhammed K, Riyaz A, et al. Drug Reaction
 with Eosinophilia and Systemic Symptoms in Children: A Prospective Study. Pediatr Dermatol.
 2016 Mar;33(2):e162–5.
- 412 23. Han XD, Koh MJ -A., Wong SMY. Drug reaction with eosinophilia and systemic symptoms in a
 413 cohort of Asian children. Pediatr Dermatol. 2019 May;36(3):324–9.
- 414 24. Lee JY, Lee SY, Hahm JE, Ha JW, Kim CW, Kim SS. Clinical features of drug reaction with
 415 eosinophilia and systemic symptoms (DRESS) syndrome: a study of 25 patients in Korea. Int J
 416 Dermatol. 2017 Sep;56(9):944-951.
- Taweesedt PT, Nordstrom CW, Stoeckel J, Dumic I. Pulmonary Manifestations of Drug Reaction
 with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review. Biomed Res
 Int. 2019 Sep 24;2019:7863815.
- 26. Do-Pham G, Charachon A, Duong TA, Thille AW, Benhaiem N, Bagot M, Chosidow O, Roujeau JC,
 Wolkenstein P, Valeyrie-Allanore L. Drug reaction with eosinophilia and systemic symptoms and
 severe involvement of digestive tract: description of two cases. Br J Dermatol. 2011
 Jul;165(1):207-9.
- 424 27. Eland IA, Dofferhoff AS, Vink R, Zondervan PE, Stricker BH. Colitis may be part of the
 425 antiepileptic drug hypersensitivity syndrome. Epilepsia. 1999 Dec;40(12):1780-3.
- 426 28. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity
 427 syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med
 428 Surg. 1996 Dec;15(4):250–7.
- 429 29. Shiohara T, Inaoka M, Kano Y. Drug-induced Hypersensitivity Syndrome(DIHS): A Reaction
 430 Induced by a Complex Interplay among Herpesviruses and Antiviral and Antidrug Immune
 431 Responses. Allergol Int. 2006 Jan 1;55(1):1–8.
- 30. Soria A, Bernier C, Veyrac G, Barbaud A, Puymirat E, Milpied B. Drug reaction with eosinophilia
 and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study. J
 Am Acad Dermatol. 2020 Mar;82(3):606-611.
- 435 31. Descamps V, Ben Saïd B, Sassolas B, Truchetet F, Avenel-Audran M, Girardin P, et al. Prise en
 436 charge du drug reaction with eosinophilia and systemic symptoms (DRESS). Ann Dermatol
 437 Vénéréologie. 2010 Nov;137(11):703–8.

- 438 32. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome. J Am Acad Dermatol. 2013
 439 May;68(5):709.e1-709.e9.
- 440 33. Funck-Brentano E, Duong T-A, Bouvresse S, Bagot M, Wolkenstein P, Roujeau J-C, et al.
 441 Therapeutic management of DRESS: A retrospective study of 38 cases. J Am Acad Dermatol.
 442 2015 Feb;72(2):246–52.
- 443 34. Uhara H, Saiki M, Kawachi S, Ashida A, Oguchi S, Okuyama R. Clinical course of drug-induced
 444 hypersensitivity syndrome treated without systemic corticosteroids: DIHS treated without
 445 systemic corticosteroids. J Eur Acad Dermatol Venereol. 2013 Jun;27(6):722–6.
- Kano Y, Horie C, Inaoka M, Ishida T, Mizukawa Y, Shiohara T. Herpes Zoster in Patients with
 Drug-induced Hypersensitivity Syndrome/DRESS. Acta Derm Venereol. 2012;92(2):206–7.
- 448 36. Ushigome Y, Kano Y, Ishida T, Hirahara K, Shiohara T. Short- and long-term outcomes of 34
 449 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad
 450 Dermatol. 2013 May;68(5):721–8.
- Joly P, Janela B, Tetart F, Rogez S, Picard D, D'Incan M, et al. Poor Benefit/Risk Balance of
 Intravenous Immunoglobulins in DRESS. Arch Dermatol. 2012 Apr 1;148(4):543–4.
- 453 38. Kito Y, Ito T, Tokura Y, Hashizume H. High-dose Intravenous Immunoglobulin Monotherapy for
 454 Drug-induced Hypersensitivity Syndrome. Acta Derm Venereol. 2012;92(1):100–1.
- 455 39. Comfere NI, Sartori-Valinotti JC, Bruce AJ, Drage LA. Successful treatment of lamotrigine456 associated drug hypersensitivity syndrome with intravenous IgG. J Am Acad Dermatol. 2012
 457 Jun;66(6):e249–50.
- 40. Marcus N, Smuel K, Almog M, Prais D, Straussberg R, Landau D, et al. Successful Intravenous
 Immunoglobulin Treatment in Pediatric Severe DRESS Syndrome. J Allergy Clin Immunol Pract.
 2018 Jul;6(4):1238–42.
- 461 41. Kuschel SL, Reedy MS. Cyclosporine treatment of drug reaction with eosinophilia and systemic
 462 symptoms (DRESS) syndrome: a case report and brief review of the literature. Pract Dermatol.
 463 2018 Oct;2018:41-43.
- 464 42. Ton A, Kassab L, Patel A, Dawson N. Severe acute hepatitis in drug reaction with eosinophilia
 465 and systemic symptoms (DRESS) syndrome resolved following cyclosporine. J Allergy Clin
 466 Immunol Pract. 2020 Jan 1;8(1):398–400.

- 467 43. Harman KE, Morris SD, Higgins EM. Persistent anticonvulsant hypersensitivity syndrome
 468 responding to ciclosporin. Clin Exp Dermatol. 2003;28(4):364–5.
- 469 44. Chen Y-C, Chang C-Y, Cho Y-T, Chiu H-C, Chu C-Y. Long-term sequelae of drug reaction with
 470 eosinophilia and systemic symptoms: A retrospective cohort study from Taiwan. J Am Acad
 471 Dermatol. 2013 Mar 1;68(3):459–65.
- 472 45. Lonowski S, Hau J, Worswick S. Vitiligo: a potential autoimmune sequela of DRESS syndrome. Br
 473 J Dermatol. 2016;175(3):642–4.
- 474 46. Kano Y, Tohyama M, Aihara M, Matsukura S, Watanabe H, Sueki H, et al. Sequelae in 145
 475 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and
 476 systemic symptoms: Survey conducted by the Asian Research Committee on Severe Cutaneous
 477 Adverse Reactions (ASCAR). J Dermatol. 2015;42(3):276–82.
- 478 47. Aota N, Hirahara K, Kano Y, Fukuoka T, Yamada A, Shiohara T. Systemic Lupus Erythematosus
 479 Presenting with Kikuchi-Fujimoto's Disease as a Long-Term Sequela of Drug-Induced
- 480 Hypersensitivity Syndrome. Dermatology. 2009;218(3):275–7.
- 481 48. Lehloenya RJ, Peter JG, Copascu A, Trubiano JA, Phillips EJ. Delabeling Delayed Drug
 482 Hypersensitivity: How Far Can You Safely Go? J Allergy Clin Immunol Pract. 2020 Oct;8(9):2878-
- 483 2895.e6.
- 484 49. Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, et al. A multicentre
- study to determine the value and safety of drug patch tests for the three main classes of severe
 cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555–62.

487 Figure and Table Legends

488 **Figure 1.** 3 years old child with diffuse maculopapular rash, facial edema and cheilitis.


Figure 2. Culprit drug initiation, Clinical & Biological Events Timeline in relation to onset of rash (defined as Day 0). This box-plot reports the time between drug initiation (drugs of probable and definite probability according to Naranjo criteria (11)) in relation to the onset of the rash (left side) and time between diagnosis of DRESS syndrome, biological parameters (eosinophil and transaminase peak, transaminase resolution) and rash resolution in relation to the onset of the rash (right side).


497 Table 1. Demographics and characteristics of patients and DRESS syndrome


498

499 **Table 2. Clinical features**

- 500 Table 3. Biological characteristics
- 501







Rash Onset

				n = 49	%
Age, median (range)				8 (5 weeks	-18 years
Sex	Male			22	44.9
JEX	Female	9		27	55.1
History of cutaneous drug r	eaction			3	6.1
	Allergy (other than drug reaction)			5	10.2
Comorbidity	Atopy			3	6.1
comorbiaity	Epilepsy	y		16	32.7
	Immunodepression ^a			8	16.3
RegiSCAR score	Probable (4-5)			22	44.9
Regiscan score	Definite (≥ 6)			27	55.1
Time from onset of rash to	diagnosis of DRES	SS (day	ys), median (range)	6 (0-28)	
	Dermatologist			28	57.1
	Pediatrician			6	12.2
Specialist establishing the	Allergologist			4	8.2
diagnosis of DRESS	Intensive care a	anesth	etist	2	4.1
	Infectious disease specialist			1	2
	Pharmacovigila	ance sy	vstem	1	2
					28.6
	Viral infection			14	[63.6]
	Kawasaki diseas	se		5	10.2
					[22.7]
		Exanth	em following amoxicillin during		
Differential diagnosis		monor	nucleosis		
[n = 22 children]		Scarlet			
	Others Ery Pseu Mal		hock syndrome		14.3
			ema multiforme	7	[31.8]
			olymphoma		
		arthrit	ant hemopathy or Juvenile idiopathic		
			generalized exanthematous pustulosis		
	None			3	6.1
	Topical		Total	25	51
	corticosteroid		Topical corticosteroids only	15	30.6
				27	
			Systemic corticosteroid (median	14 (42.5	
Treatment of DRESS			duration)	days)	55.1
syndrome	Systemic therapy		IV then oral	3 (2	24.5
		ру	IV only	days)	10.2
			, Oral only	10 (44.5	20.4
			Intravenous Immunoglobulin	days)	
			Cyclosporin	6	12.2
			Cyclosporm		4.1
Hospitalization in intensive	care unit		2 17		34.7
Duration of stay in intensive		medi	an (range)	5 (1-26)	5
Suration of stay in intensiv	e cure unit (uays),	, meun	2 (. 3.18c)	13 (3-60)	
Duration of hospitalization (days), median (range) : all				13 (3-00) 10 (3-39)	
Community cases					
Hospital cases (n = 12) ^b	22 (12-				
				60)	

Table 1: Demographics and characteristics of patients and DRESS syndrome

Relapse ^c	11	22.4		
Death	2	4.1		
^a Immunodepression : dialysis chronic kidney disease; IgG4 deficiency; cystic fibrosis, acute lymphocytic leukemia under				
chemotherapy; vasculitis under corticosteroids and cyclophosphamide; hydrocephalus under corticosteroids; 2				
autoinflammatory diseases under IL-1-blocking agent. ^b Duration of stay after onset of rash. ^c Relapse: recurrence of clinical				
or biological signs after their normalisation in the absence of reintroduction of culprit drug				
RegiSCAR: Registry of Sever Cutaneous Adverse Reaction; IV: Intravenous				

Table 2: Clinical features

		n = 49	%
Fever (temper	rature > 38.5°C)	49	100
Rash		49	100
Morbilliforn	n (maculopapular)	33	67.3
Monomorp	hic	22 ^a	44.9
Polymorph	ic	11	22.4
Macular		3	6.1
Nonspecifie	d	7	14.3
Erythrodern	na	7 ^a	14.3
	Purpura	9	18.4
	Pustules	5	10.2
Associated	Target-like lesions	3	6.1
skin lesions	Urticaria	2	4.1
	Eczema-like lesions	1	2
	Blisters	1	2
	[Case where answer is available n = 43]		
Body	< 50 %	2	4.1 [4.6]
surface area	50 - 90 %	31	63.3 [72.1]
	> 90 %	10	20.4 [23.3]
Rash duration	(days), median (range) [Case where answer is available n = 40]	20.5 (4-90)	
< 15 days		11	22.4 [27.5]
15 - 29 days		18	36.7 [45]
≥ 30 days		11	22.4 [27.5]
Pruritus [Case	where answer is available n = 39]	33	67.3 [84.6]
Edema (total)	[Case where answer is available n = 42]	34	69.4 [81]
Facial		32	65.3 [76.2]
Extremities		11	22.4
Generalized		3	6.1
Lymphadenop	bathy [Case where answer is available n = 44]	34	69.4 [77.3]
Hepatomegal	y [Case where answer is available n = 37]	12	24.5 [32.4]
Splenomegaly	ا [Case where answer is available n = 33]	7	14.3 [21.1]
Mucosal invol	vement [Case where answer is available n = 41]	20	40.8 [48.8]
Lips		15	30.6
Mouth/thro	at	8	16.3
Eyes		5	10.2
	Liver (elevated transaminases)	41	83.7
	Kidney (Table 3)	13	26.5
Internal	Lung (3 interstitial infiltrate, 3 ARDS (2 with orotracheal	11	22.4
organ	intubation), 2 broncho-obstructive syndrome, 1 alveolar		
involvement	infiltrate, 1 pleural effusion, 1 nocturnal desaturation)		
	Gastrointestinal tract (5 diarrhea, 1 with vomiting)	5	10.2
	Heart (myocarditis)	1	2
	Central nervous system (meningitis)	1	2
^a A child with in	itial morbiliform exanthema presented with erythroderma when rel	lapsing	
	espiratory Distress Syndrome		

Table 3: Biological characteristics

	n = 49	%
Eosinophilia	42	85.7
500 - 749/mm³ or < 10%	3	6.1
750 - 1500 x10 ⁹ /mm³ or 10-20%	8	16.3
> 1500 x10 ⁹ /mm ³ or > 20%	31	63.3
Eosinophils peak (days after onset of rash) , median (range)	10 (0-35)	
Absolute count (/mm ³), median (range)	2585 (610-2	10 000)
Atypical lymphocytes [Cases where response is available n = 33]	24	49 [72.7]
Elevated transaminases > 2 limit of normal	41	83.7
Transaminases peak (days after onset of rash) , median (range)	11 (1-35)	
Transaminases resolution (days after onset of rash), median (range)	28 (7-68)	
Kidney	13	26.5
Proteinuria	7	14.3
Creatinine elevation (1.2 ULN; 1.35 ULN; 1.9 ULN; 2.8 ULN; 4.5 ULN)	5	10.2
Electrolyte disturbance	2	4.1
Hematuria	1	2
Patients profils:	n=13	
Proteinuria only	7	53.8
Creatinine elevation only	4	30.8
Creatinine elevation + Electrolyte disturbance + anuria	1	7.7
Hematuria + Electrolyte disturbance+ polyuria	1	7.7
TSH elevation (8.6 UI/L)	1	2
Lipase elevation (1025 UI/L)	1	2
Biological criteria for Haemophagocytic lymphohistiocytosis ^a	12	24.5
Viral reactivation or infection		
Total positive PCR and/or Serology [Tested cases n = 42]	17	34.7 [40.5]
Positive viral PCR ^b [Tested cases $n = 34$]	17	34.7 [50]
HHV-6 [Tested cases n = 32]	7	14.3 <i>[21.9]</i>
HHV-7 [Tested cases n = 12]	2	4.1 <i>[16.7]</i>
Parvovirus B19 [Tested cases n = 21]	4	8.2 [19]
EBV [Tested cases n = 29]	4	8.2 [13.8]
CMV [Tested cases n = 31]	2	4.1 [6.5]
Positive serology for IgM [Tested cases n = 26]	3	6.1 [11.5]
EBV ^c [Tested cases n = 24]	2	4.1 [8.3]
VZV ^d	1	2

^a 3 or more of the following criteria: elevated transaminases, bicytopenia, hyperferritinemia >500 ng/ml, lactate deshydrogease elevation, hypertriglyceridemia >3 mmol/L or hypofibrinemia <1.5g

^b 34 children were investigated by polymerase chain reaction (PCR) : 17 (44.7%) were positive, including two children with EBV + CMV.

^c Among the 26 children who had viral serology, 2 had results compatible with EBV primary infection (VCA-IgM positive and no IgG): first case had also a positive parvovirus B19 PCR, and second case had also a positive EBV PCR.

^d One child had results compatible with VZV primary infection, who is also one of child with the EBV + CMV co-reactivation.

CE: Creatinine elevation, CMV: Cytomegalovirus, EBV: Epstein-Barr virus, HHV: Human Herpes Virus, PCR: Polymerase Chain Reaction, TSH: thyroid-stimulating hormone; ULN: upper limit of normal; VZV: Varicellazoster virus